First-Ever Point-Of-Care COVID-19 Serology Test Granted EUA By FDA
Executive Summary
The US agency on 23 September granted emergency use authorization for the Assure COVID-19 IgG/IgM Rapid Test Device to be used in point-of-care settings like doctor’s offices, hospitals, urgent care centers and emergency rooms. The test requires a fingerstick to draw blood.
You may also be interested in...
COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.
FDA Eager To Authorize More Rapid Antigen COVID-19 Tests
The US FDA’s diagnostics chief says the agency isn’t seeing many submissions for rapid antigen tests, but is eager to authorize them.